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V
asculitides encompass a group of
rare autoimmune diseases where
inflammation of vessels causes
multisystem organ damage (i.e. kidneys,
lungs, nervous system, Figure 1). The
overall incidence is currently estimated to
be 10-20/million/year, however there is
an increasing trend noted in the pediatric
population in Alberta1,2.
As with other rare autoimmune diseases such
as lupus, the limited number of patients impairs
recruitment into clinical trials, impedes research, and
hinders the generation of evidence-based treatment
recommendations and protocols4. Moreover, the
low patient numbers provide a barrier to obtaining
reliable rare disease prevalence statistics and to
gaining a clear understanding of the natural history
of specific vasculitides.
To address some of these limitations, we propose to
generate a prospective vasculitis registry for patients
in Southern Alberta. This initial registry will
serve as a foundation for collaboration with other
established or prospective centres at the provincial,
national, and international levels (Figure 2). The
contribution of Canadian centres is coordinated
through the Canadian network for research on
vasculitides (CanVasc), representing a network of
physicians with expertise in vasculitis. To ensure
the seamless amalgamation of information among
the centres, the same nomenclature and database
platform will be used by each provincial vasculitis
centre. The establishment of such a registry
will create a framework for knowledge translation,
discovery, and best practice management.
Methods
Recruitment will initially be limited to patients with
vasculitis residing in Southern Alberta who have been
referred to the Rheumatology division in Calgary
through the central triage system to ensure capture of
patients with a confirmed diagnosis. Ethics approval
for this research project was obtained in May 2012.
Patients complete written informed consent at their
baseline visit in the Rheumatology vasculitis clinic
at the South Health Campus in Calgary, Alberta.
Upon consenting, the patients are examined yearly
by Dr. Aurore Fifi-Mah, a Rheumatologist at the
South Health Campus. The research team will
complete yearly case report forms where information
on patient symptoms, test results, response to
treatment, activity of disease and complications will
be longitudinally collected. Each patient will also
complete a Patient Quality of Life form (SF-36).
Patient consent also extends to the collection of
de-identified sera for storage in the Mitogen Advanced
Diagnostics Laboratory in Calgary, Alberta, under
the direction of Dr. Fritzler. As new diagnostic and
prognostic biomarkers are identified, these sera will
constitute a biobank to be analyzed for the presence of
new target antibodies and proteins. Such information
can enhance understanding of the pathogenesis of
these diseases to inform and direct future therapeutic
approaches. Biomarkers could also help with early
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Figure 1:
The 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides3.
Figure 2:
Schematic of expansion of the Southern Alberta Vasculitis Registry. (CanVasc: Canadian network for research on
vasculitides; http://www.canvasc.ca)
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Table 1: Current numbers and proportions of patients categorized by specific vasculitides in the Southern Alberta
Vasculitis Patient Registry.
Diagnosis Number Percentage
ANCA-associated Vasculitis 12 11.2
Behc¸ets Disease 7 6.5
Connective Tissue Disease Associated Vasculitis 6 5.6
Central Nervous System Vasculitis 4 3.7
Cryoglobulinemic Vasculitis 2 1.8
Giant Cell Arteritis 9 8.4
IgA Vasculitis 5 4.6
Leukocytoclastic Vasculitis 11 10.2
Polyarteritis Nodosa 11 10.2
Polymyalgia Rheumatica 13 12.1
Takayasus Arteritis 6 5.6
Vasculitis Associated with Other Disease 22 20.5
detection of disease relapse to reduce permanent
organ damage and improve prognosis.
As this is an observational study, no power
calculation is involved. Descriptive analysis will be
used to summarize participant characteristics and
comorbid conditions.
Results
The initial project infrastructure has been successfully
established. To date, 107 patients have been recruited
(Table 1).
Discussion and Conclusions
The establishment of a Southern Alberta Vasculitis
Patient Registry allows the development of a
prospective cohort of patients with vasculitis seen
in Calgary, the catchment area for Southern Alberta.
The data collected include clinical and serological
information that will be captured in a database. The
development of a biobank of sera with access to an
internationally recognized immunology laboratory in
Calgary will provide the basic science and technical
support to improve diagnosis and management of
patients based on their biomarker profile. This will
help address issues of inaccurate rare disease statistics,
inadequate understanding of disease natural history,
and limited diagnostic and treatment regimes.
Through systematic collection and analysis of data,
the registry will create a foundation of knowledge on
which to build informed, standardized models of care
by identifying gaps in patient care.
Moreover, the additional benefit of serum analysis
may permit the discovery of specific biomarkers and
prognostic factors to classify and predict the future
course of different vasculitis subtypes. This will
permit individualized, patient-centred treatment.
The extension of this project to include centres
provincially, nationally, and internationally would
magnify the utility of the initial project. The previous
establishment of provincially-based vasculitis research
centres through CanVasc expedites project expansion.
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